Provided by Tiger Trade Technology Pte. Ltd.

Vir Biotechnology, Inc.

8.97
-0.1299-1.43%
Volume:352.87K
Turnover:3.18M
Market Cap:1.41B
PE:-2.84
High:9.24
Open:9.12
Low:8.89
Close:9.10
52wk High:10.94
52wk Low:4.16
Shares:157.00M
Float Shares:107.00M
Volume Ratio:1.86
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1619
EPS(LYR):-3.1619
ROE:-45.73%
ROA:-24.36%
PB:1.84
PE(LYR):-2.84

Loading ...

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing Eclipse Clinical Development Program

THOMSON REUTERS
·
Dec 17, 2025

Vir Biotechnology - to Receive EUR 55 Mln Initial Reimbursement Payment Upon Closing , EUR 495 Mln in Clinical, Regulatory and Sales Milestones

THOMSON REUTERS
·
Dec 17, 2025

Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy

Simply Wall St.
·
Dec 08, 2025

Director Vicki L. Sato Reports Sale of Vir Biotechnology Inc. Common Shares

Reuters
·
Dec 03, 2025

SVF Endurance (Cayman) Ltd Reports Disposal of Vir Biotechnology Inc. Common Shares

Reuters
·
Dec 02, 2025

Vaccine Stocks Falls as FDA Vows to Impose New Vaccine Requirements

Tiger Newspress
·
Dec 01, 2025

SVF Endurance (Cayman) Ltd Reports Disposal of Vir Biotechnology Common Shares

Reuters
·
Nov 27, 2025

H.C. Wainwright Keeps Their Buy Rating on Vir Biotechnology (VIR)

TIPRANKS
·
Nov 22, 2025

Vir Biotechnology CEO to Join Evercore Healthcare Conference Fireside Chat

Reuters
·
Nov 20, 2025

Barclays Sticks to Their Buy Rating for Vir Biotechnology (VIR)

TIPRANKS
·
Nov 12, 2025

Stock Track | Vir Biotechnology (VIR) Soars 5.03% as Analysts Maintain Buy Ratings

Stock Track
·
Nov 12, 2025

Stock Track | Vir Biotechnology (VIR) Soars 5.03% on Bullish Analyst Ratings

Stock Track
·
Nov 12, 2025

Morgan Stanley Sticks to Its Buy Rating for Vir Biotechnology (VIR)

TIPRANKS
·
Nov 11, 2025

Vir Biotechnology (VIR) Gets a Buy from TD Cowen

TIPRANKS
·
Nov 11, 2025

Some Analysts Just Cut Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates

Simply Wall St.
·
Nov 10, 2025

Stock Track | Vir Biotechnology Surges 11.11% Pre-market on Promising Hepatitis Delta Treatment Results

Stock Track
·
Nov 10, 2025

Stock Track | Vir Biotechnology Soars 8.38% on Positive Phase 2 Results for Hepatitis Delta Treatment

Stock Track
·
Nov 10, 2025

Stock Track | Vir Biotechnology Soars 8.38% on Positive Phase 2 Results for Hepatitis Delta Treatment

Stock Track
·
Nov 10, 2025

Vir Biotechnology announces Week 48 endpoint analysis of Phase 2 SOLSTICE

TIPRANKS
·
Nov 10, 2025

Vir Biotechnology Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta

Reuters
·
Nov 10, 2025